The efficacy of valproate in acute mania, bipolar depression and maintenance therapy for bipolar disorder: an overview of systematic reviews with meta-analyses.

Autor:	Mari J; Universidade Federal de São Paulo, Sao Paulo, Brazil jamari17@gmail.com., Dieckmann LHJ; Brazilian Institute of Practical Psychopharmacology, São Paulo, Brazil., Prates-Baldez D; Laboratory of Molecular Psychiatry, UFRGS, Porto Alegre, Brazil., Haddad M; Brazilian Institute of Practical Psychopharmacology, São Paulo, Brazil., Rodrigues da Silva N; Brazilian Institute of Practical Psychopharmacology, São Paulo, Brazil., Kapczinski F; Department of Psychiatry and Behavioural Neurosciences, Hamilton, Stockholm, Sweden.; Department of Psychiatry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2024 Nov 05; Vol. 14 (11), pp. e087999. Date of Electronic Publication: 2024 Nov 05.
DOI:	10.1136/bmjopen-2024-087999
Abstrakt:	Objective: This study aims to conduct an overview on the comparative efficacy of valproate in acute mania, bipolar depression and maintenance treatment of bipolar disorder (BD). Method: We performed an overview of systematic reviews with meta-analyses of randomised controlled trials (RCTs), registered in PROSPERO (CRD42024497749). We searched Medline and Cochrane Database of Systematic Reviews. Summary measures comparing valproate with placebo or other active drugs were described. Results: We included 26 systematic reviews. For acute mania (31 RCTs, n=4376), valproate showed a significantly better response than placebo in two high-quality systematic reviews (RR=1.42; 95% CI: 1.19 to 1.71) (OR=2.05; 95% CI: 1.32 to 3.20). No significant differences with lithium were found in most outcomes. Valproate had similar efficacy to quetiapine and lower efficacy compared with risperidone, with conflicting results when compared with olanzapine. In bipolar depression (7 RCTs, n=399), valproate was more effective than placebo in reducing depressive symptoms (OR=2.80; 95% CI: 1.26 to 6.18) and achieving remission (OR=2.4; 95% CI: 1.09 to 5.29) (OR=2.15; 95% CI: 0.82 to 5.6), considering the results of three high-quality systematic reviews. No significant difference was observed with lithium, lurasidone, quetiapine or olanzapine plus fluoxetine, but valproate showed superior efficacy to aripiprazole, ziprasidone and agomelatine. In maintenance treatment (11 RCTs, n=1063), valproate was superior to placebo in preventing relapse of any mood episode in two high-quality systematic reviews (RR=0.63; 95% CI: 0.48 to 0.83) (RR=0.63; 95% CI: 0.47 to 0.83). No significant difference was found with lithium, olanzapine or lamotrigine. Conclusion: This overview highlights favourable results for valproate compared with placebo in all phases of BD, as well as presenting specific results in comparison with other active drugs. However, these results must be interpreted considering the methodological limitations of our study. Competing Interests: Competing interests: This article was funded by a grant from the Abbott Laboratories in the provision of study material and on review process, and article processing charges, there was no involvement of medical writing. The paper was prepared by the investigators with independency and autonomy. Grant number: RRTI-8293. JMM has recieved honoraria for lectures for Apsen, Janssen, Abbot, EMS, and Biolab. LHJD has received fees as a consultant from Apsen, Abbot, AbbVie, Biolab, Cristália, Daichii-Sankyo, EMS, Gntech, Inspirali, LIBBS, Lundbeck, Mantecorp, Moksha 8, Pfizer, Sanofi, Servier, Viatris, FQM, Takeda-Shire, Torrent, Artmed, Biopas, Genon, Besins, Greencare, TEVA, Aché. MH has recieved fees as consultant from Apsen, Abbot, Biolab, Cristália, Daichii-Sankyo, EMS, Gntech, Johnson&Johnson, LIBBS, Lundbeck, Mantecorp, Moksha 8, Pfizer, Sanofi, Servier, Viatris, Takeda-Shire, Torrent, Biopas. FK has received personal fees as a speaker/consultant from Janssen (Johnson & Johnson), Daiichi-Sankyo, Libbs, Abbott and Teva Pharmaceutical Industries. DPB and NRS declare no conflict of interest. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu